WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2014179626) COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2014/179626    International Application No.:    PCT/US2014/036462
Publication Date: 06.11.2014 International Filing Date: 01.05.2014
IPC:
A61K 31/7125 (2006.01)
Applicants: ISIS PHARMACEUTICALS, INC. [US/US]; 2855 Gazelle Court Carlsbad, CA 92010 (US)
Inventors: PRAKASH, Thazha, P.; (US).
SETH, Punit, P.; (US).
SWAYZE, Eric, E.; (US).
GRAHAM, Mark, J.; (US)
Agent: LIANG, Teresa, Y.; (US)
Priority Data:
61/880,790 20.09.2013 US
61/986,867 30.04.2014 US
61/871,673 29.08.2013 US
61/823,826 15.05.2013 US
61/818,442 01.05.2013 US
61/976,991 08.04.2014 US
61/843,887 08.07.2013 US
Title (EN) COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN C-III EXPRESSION
(FR) COMPOSITIONS ET PROCÉDÉS DE MODULATION DE L'EXPRESSION DE L'APOLIPOPROTÉINE C-III
Abstract: front page image
(EN)Provided herein are oligomeric compounds with conjugate groups targeting apoplipoprotein C-III (ApoClll). In certain embodiments, the ApoClll targeting oligomeric compounds are conjugated to N-Acetylgalactosamine. Also disclosed herein are conjugated oligomeric compounds targeting ApoClll for use in decreasing ApoClll to treat, prevent, or ameliorate diseases, disorders or conditions related to ApoClll. Certain diseases, disorders or conditions related to ApoClll include inflammatory, cardiovascular and/or metabolic diseases, disorders or conditions. The conjugated oligomeric compounds disclosed herein can be used to treat such diseases, disorders or conditions in an individual in need thereof.
(FR)L'invention concerne des composés oligomères avec des groupes conjugués ciblant l'apolipoprotéine C-III (ApoClll). Dans certains modes de réalisation, les composés oligomères ciblant l'ApoClll sont conjugués à la N-acétylgalactosamine. L'invention concerne également des composés oligomères conjugués ciblant l'ApoClll utilisés pour réduire l'ApoClll afin de traiter, prévenir ou améliorer des maladies, affections ou pathologies associées à l'ApoClll. Les maladies, affections ou pathologies inflammatoires, cardiovasculaires et/ou métaboliques figurent parmi les maladies, affections ou pathologies associées à l'ApoClll. Les composés oligomères conjugués décrits ici peuvent être utilisés pour traiter ces maladies, affections ou pathologies chez un patient ayant besoin d'un tel traitement.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)